PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Grallert, H. ; Marzi, C. ; Hauck, S.M. ; Gieger, C.

Omics: Potential role in early-phase drug development.

In: Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. London: Springer, 2015. 189-222
DOI
The development of high-throughput omics technologies has nourished the hope to improve our understanding and treatment of the pathophysiology of globally increasing diseases such as type 2 diabetes and obesity. These technologies provide innovative tools that have the potential to truly revolutionize patient care. Technologies continue to propel the omics fields forward. However, translating research discovery into routine clinical applications use is a complex process not only from scientific prospective but also from ethical, political, and logistic points of view. Particularly the implementation of omics-based tests requires changes in fundamental processes of regulation, reimbursement, and clinical practice. Altogether, developments in the field of omics technologies hold great promise to optimize patient care and improve outcomes and eventually lead to new tests that are well integrated in routine medical care.
Scopus
Cited By
Altmetric
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Edited volume or book chapter
Editors Krentz, A.J.* ; Heinemann, L.* ; Hompesch, M.*
Keywords Genomics; Epigenomics; Transcriptomics; Proteomics; Metabolomics; Microarray; Sequencing; Disease prediction; Pharmacogenomics; Personalized medicine
Language english
Publication Year 2015
HGF-reported in Year 2015
e-ISSN 978-1-4471-4920-0
ISBN 978-1-4471-4919-4
Book Volume Title Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development
Quellenangaben Volume: , Issue: , Pages: 189-222 Article Number: , Supplement: ,
Publisher Springer
Publishing Place London
Institute(s) Institute of Epidemiology (EPI)
CF Metabolomics & Proteomics (CF-MPC)
POF-Topic(s) 30202 - Environmental Health
30203 - Molecular Targets and Therapies
90000 - German Center for Diabetes Research
Research field(s) Genetics and Epidemiology
Enabling and Novel Technologies
PSP Element(s) G-504091-002
G-504091-004
G-505700-001
G-501900-402
DOI 10.1007/978-1-4471-4920-0_8
Scopus ID 84948807666
Erfassungsdatum 2015-11-18
[➜Report correction]